Lipigon Pharmaceuticals (LPGO.ST) Stock Analysis & AI Equity Report
Lipigon Pharmaceuticals (LPGO.ST) overview
Lipigon Pharmaceuticals (LPGO.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Lipigon Pharmaceuticals reported revenue of SEK 10.3m and operating profit of SEK -26.3m; the year-end share price was 0.12 SEK and market capitalisation was SEK 16.0m. Lipigon Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Lipigon Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-29. Data will be refreshed during report generation.
About Lipigon Pharmaceuticals
Lipigon Pharmaceuticals AB is a clinical-stage pharmaceutical company focused on developing treatments for diseases linked to abnormal lipid metabolism. Its lead candidate, Lipisense, is designed to lower triglyceride levels in patients with elevated blood lipids, and the company is advancing three projects based on different mechanisms of action across lipid-related disorders.
Generate the Lipigon Pharmaceuticals report
Lipigon Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Lipigon Pharmaceuticals and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.